[Clinical effect of tocilizumab on patients with severe active rheumatoid arthritis].
To evaluate therapeutic effects and adverse reactions of tocilizumab on patients with severe active rheumatoid arthritis (RA). Methods: Twelve patients with severe refractory RA were treated with tocilizumab. The clinical and laboratory indices and the side effects were recorded after treatment. Results: The clinical and laboratory indices and the disease activity score 28 (DAS28) were observed in all patients, which were significantly improved after TCZ therapy (P<0.05), and no obvious adverse reactions were found. Conclusion: Tocilizumab can effectively relieve the symptoms and improve the conditions of severe active RA.